- Home
- NVO vs AZN Comparison
NVO vs AZN Comparison
Compare NVO & AZN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NVO
- AZN
- Stock Information
- Founded
- NVO 1923
- AZN 1992
- Country
- NVO Denmark
- AZN United Kingdom
- Employees
- NVO N/A
- AZN N/A
- Industry
- NVO Biotechnology: Biological Products (No Diagnostic Substances)
- AZN Biotechnology: Pharmaceutical Preparations
- Sector
- NVO Health Care
- AZN Health Care
- Exchange
- NVO Nasdaq
- AZN Nasdaq
- Market Cap
- NVO 278.0B
- AZN 252.9B
- IPO Year
- NVO N/A
- AZN 1993
- Fundamental
- Price
- NVO $54.36
- AZN $84.62
- Analyst Decision
- NVO Buy
- AZN Strong Buy
- Analyst Count
- NVO 9
- AZN 1
- Target Price
- NVO $80.40
- AZN N/A
- AVG Volume (30 Days)
- NVO 13.1M
- AZN 6.1M
- Earning Date
- NVO 11-05-2025
- AZN 11-11-2025
- Dividend Yield
- NVO 2.26%
- AZN 1.81%
- EPS Growth
- NVO 24.25
- AZN 28.86
- EPS
- NVO 3.93
- AZN 5.31
- Revenue
- NVO $49,108,936,497.00
- AZN $56,501,000,000.00
- Revenue This Year
- NVO $9.58
- AZN $10.82
- Revenue Next Year
- NVO $7.39
- AZN $5.99
- P/E Ratio
- NVO $13.84
- AZN $15.95
- Revenue Growth
- NVO 20.91
- AZN 15.00
- 52 Week Low
- NVO $45.05
- AZN $61.24
- 52 Week High
- NVO $119.07
- AZN $86.57
- Technical
- Relative Strength Index (RSI)
- NVO 38.41
- AZN 61.24
- Support Level
- NVO $55.80
- AZN $83.10
- Resistance Level
- NVO $57.55
- AZN $85.15
- Average True Range (ATR)
- NVO 1.36
- AZN 1.58
- MACD
- NVO -0.43
- AZN 0.12
- Stochastic Oscillator
- NVO 11.07
- AZN 84.54
About NVO Novo Nordisk A/S
With roughly one third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (constituting less than 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.
About AZN AstraZeneca PLC
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across a number of major therapeutic areas, including oncology (about 40% of total revenue), cardiovascular, renal, and metabolic (25%), rare disease (17%), and respiratory and immunology (15%). The majority of sales comes from international markets, with the United States representing close to one third of its sales.